These anti-angiogenesis approaches, combined with direct anti-OPG antibody targeting, can be combined with existing chemotherapies or checkpoint inhibitors routinely used in the treatment of breast cancer for a synergistic therapeutic effect. This evidence concerns the gene TNFRSF11B and breast carcinoma.